AB011

News alerts, weekly reports and conference planners

Company:

CARsgen

Drug class:

CLDN18.2 inhibitor

Related drugs:

CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	AB011 Sensitive: C2 – Inclusion Criteria AB011 Sensitive : C2	AB011 Sensitive: C2 – Inclusion Criteria AB011 Sensitive : C2
CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	AB011 Sensitive: C3 – Early Trials AB011 Sensitive : C3	AB011 Sensitive: C3 – Early Trials AB011 Sensitive : C3

Associations
(2)